Skip to main content
BMYBristol-Myers Squibb CompanyHold6.2·$64.92+2.89%
BMY · Why this verdict

Why Bristol-Myers Squibb (BMY) is rated HOLD

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictHOLD
Overall score6.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis

Engine thesis — one sentence

A high-quality pharmaceutical franchise with a Piotroski F-Score of 7 out of 9, 135% free cash flow conversion, and four consecutive earnings beats averaging 14% above estimates is priced with just 0.9% headroom to the price target; momentum is at the minimum threshold with falling on-balance volume, and a 448% dividend payout ratio cannot be sustained from current earnings — the setup favors holding an existing position rather than deploying new capital.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

Four consecutive quarters have come in above consensus estimates, with an average positive surprise of 14% and the most recent beat at 11%, supported by a Piotroski F-Score of 7 out of 9 and free cash flow converting at 135% of net income — indicating operational quality that runs above the income statement alone.

Stable
Earnings
Expectation
The beat streak extends to 6 consecutive quarters and free cash flow conversion remains above 100% of net income over the next 12 months.

CounterAn average surprise of 14% could reflect analysts consistently setting conservative estimates; if top-line growth remains muted, any guidance-setting normalization could break the streak without a change in underlying business performance.

With only 0.9% remaining headroom to the price target and a risk/reward ratio well below the minimum bar for a new position, the operational story has been largely recognized by the market at current prices — the setup favors patience over new capital deployment.

Deteriorating
Price targets
Expectation
Price declines below $50.00, creating more than 13% upside to the current price target and reopening a favorable entry setup.

CounterIf analyst targets are revised higher on the back of continued earnings beats, the apparent ceiling rises and the current price could still represent positive expected value for a longer holding horizon.

A dividend payout ratio of 448% of earnings — flagged as a yield trap with an unsafe payout — combined with a debt-to-equity ratio of 2.3x leaves the capital structure exposed if cash generation softens, since the distribution appears to require sources beyond current net income to sustain.

Stable
Catalyst breakdown
Expectation
The dividend payout ratio falls below 100% of earnings for 2 consecutive quarters, demonstrating that earnings growth has caught up with the distribution commitment.

CounterThe 135% free cash flow conversion rate indicates more cash is generated than the GAAP earnings line implies; a high dividend payout relative to net income may not signal the same stress as it would in a cash-poor business.

Momentum is at the minimum acceptable threshold — at the floor rather than comfortably above it — with on-balance volume falling, indicating that distribution rather than accumulation is occurring despite the stock remaining above its 200-day moving average.

Improving
Momentum breakdown
Expectation
RSI rises above 60 and on-balance volume turns consistently positive for 4 consecutive weeks, signaling renewed buyer participation.

CounterWith RSI at 43 mid-range and the stock still above its 200-day moving average, the momentum weakness is not yet oversold; a modest catalyst such as an earnings beat could quickly re-engage buyers without a meaningful price decline first.

Per-dimension breakdown

Value

6.4/10data confidence 100%
ComponentSub-score
P/E7.2
P/S8.5
EV/EBITDA6.7
Fwd P/E9.3
PEG4.9
Analyst target3.0
  • Forward P/E: 10.2x
  • PEG: 1.65

Quality

7.7/10data confidence 100%
ComponentSub-score
ROE10.0
ROA7.1
Gross margin10.0
Op margin10.0
Net margin7.5
Current ratio5.3
FCF quality9.5
Moat6.4
Rule of 403.0
Piotroski F7.8
  • Excellent ROE: 39%
  • Strong margins: 15%
  • Excellent cash conversion: 135% FCF/NI
  • Rule of 40: 23 (fail)

Growth

3.5/10data confidence 67%
ComponentSub-score
Rev growth3.1
EPS growth3.8

Momentum

8.2/10data confidence 100%
ComponentSub-score
RSI4.3
MACD10.0
OBV10.0
MA position9.0
Volume7.8
  • Overbought (RSI 75)
  • Volume accumulation (rising OBV)
  • Above 200-day MA

Sentiment

6.8/10data confidence 100%
ComponentSub-score
LLM sentiment8.1
Analyst rating7.5
Price target4.6
  • LLM news sentiment: +0.62 (n=5)

Insider

7.3/10data confidence 75%
ComponentSub-score
materiality5.0
holder change10.0
notable moves7.0
  • No net insider activity — $0 (0.000% of mkt cap)
  • Institutions accumulating

Peer rank

4.0/10data confidence 80%
ComponentSub-score
value rank6.6
quality rank4.9
growth rank3.1

Technical

3.5/10data confidence 100%
ComponentSub-score
bollinger0.0
support resistance0.8
52w position9.8

Risk (lower is worse)

7.3/10data confidence 100%
ComponentSub-score
short interest8.9
days to cover7.4
volatility5.6
put call9.5
implied vol6.8
beta10.0
debt equity2.7
  • Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Catalyst

7.0/10data confidence 100%
ComponentSub-score
erm5.0
earnings history10.0
earnings timing5.0
surprise avg9.5
dividend safety4.2
news activity8.0
  • Perfect beat streak: 4Q
  • Earnings in 0 days
  • Dividend: 4.0%

How the verdict was assembled

Engine trigger

Downgraded from BUY WAIT — price $64.86 has reached target $64.25. No upside to wait for.

Engine technical detail
verdict_path: L3:NEWS_BLOCK|SANITY:WAIT+price>=TP
Passed (6)
  • MOMENTUM:8.2>=5.5
  • INSIDER:OK
  • 8K:CLEAN
  • NEWS_BOOST:EARNINGS:0.70
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
  • ASYMMETRY:-1.0=NEGATIVE
  • EARNINGS_PROXIMITY:0d<=7d
Warning (0)

none

Reward-to-Risk
-0.97
Upside
-12.6%
Downside
13.0%
Sizing output
AVOID

Setup No clear chart pattern; technical signals are mixed

EdgeNo clear edge No clear edge identified

SuitabilityConservative Beta 0.23<0.8, Div 4.0%, Q=7.7

Investment implication

A recent news event triggered an L3 news-block on the verdict path. Trigger: Downgraded from BUY WAIT — price $64.86 has reached target $64.25. No upside to wait for. The 10-dimension scores remain Momentum at 8.2 (strongest), but ASYMMETRY:-1.0=NEGATIVE also fails — the news block is the proximate trigger, not the sole driver.

The strongest dimensions are Momentum at 8.2, Quality at 7.7, and Insider at 7.3; the weakest are Technical at 3.5, Growth at 3.5, and Peer rank at 4.0. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of -0.97 and an engine sizing output of AVOID.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Consistent Earnings Beat Quality

    Trip ifEPS surprise falls below 0% for 2 consecutive quarters.

  • P2Fully Priced Limited Room

    Trip ifPrice declines below $50.00, creating more than 13% upside to the current price target.

  • P3Dividend Payout And Leverage Strain

    Trip ifDividend payout ratio falls below 100% of earnings for 2 consecutive quarters.

  • P4Momentum At Floor Falling Volume

    Trip ifRSI rises above 60 and on-balance volume turns positive for 4 consecutive weeks.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home Stocks BMY Why this verdict